Aligos Therapeutics Aktie Logo
US01626L2043
A40LQ4

Aligos Therapeutics Aktie

Prévisions

L'objectif de cours moyen des analystes est de 18,23 € (+1 485,22 %). La médiane est de 18,23 € (+1 485,22 %).

Acheter
  3
Conserver
  2
Vendre
  0

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • Aligos Therapeutics presents two-pillar strategy against hepatitis B with pevifoscorvir and ALG‑170675

    At the Cantor Fitzgerald Healthcare Conference, Aligos Therapeutics unveiled an HBV strategy combining pevifoscorvir (a capsid-assembly modulator) for chronic suppression with the antisense oligonucleotide ALG‑170675 as a route toward functional cure. Pevifoscorvir showed high potency, good oral bioavailability and sustained S-antigen reduction in phase‑I data; a phase‑II superiority study versus tenofovir was expanded after an interim analysis did not meet the futility threshold. ALG‑170675 has entered clinical development in China and is intended to show additive to synergistic effects in combination with pevifoscorvir, substantially enlarging the addressable patient population. Further progress depends on ongoing clinical data and regulatory steps. » Plus sur de.investing.com


  • Aligos Therapeutics rises 7.6% premarket after sustained positive momentum

    Aligos Therapeutics shares climbed 7.6% in premarket trading to $6.55, despite no company-specific news that day. The move was driven by continued positive sentiment following strong Q2 results showing a significantly smaller net loss and an EPS beat, and by non-dilutive funding from a licensing agreement for Pevifoscorvir sodium in China. In addition, full patient recruitment for the Phase-2 B-SUPREME study was completed, reducing pipeline risk. The outperformance came despite weaker U.S. indices, and the stock remains well below its 52-week high of $13.69. » Plus sur de.investing.com


  • Aligos completes patient recruitment for phase‑2 study B‑SUPREME

    Aligos has completed recruitment for both parts of the phase‑2 B‑SUPREME study of pevifoscorvir sodium in chronic hepatitis B (131 HBeAg‑positive in part 1a, 114 HBeAg‑negative in part 2a). The larger participant number in part 1a made a second interim sample‑size analysis unnecessary. The stock rose 13% on the news last week but is down 29% year‑to‑date; the company has a market capitalization of USD 41 million and more cash than debt. Key safety and efficacy data are expected in late Q3 2027. » Plus sur de.investing.com


  • Aligos Therapeutics receives $25m upfront payment for Greater China license, shares rise

    Aligos Therapeutics received an upfront payment of $25 million from Xiamen Amoytop for an exclusive license to Pevifoscorvir sodium for the treatment of chronic HBV infections in Greater China. In addition, up to $420 million in milestone payments and tiered royalties in the high single-digit percentage range were agreed. The payment is likely to extend the cash runway into the fourth quarter of 2026, while Aligos retains commercial and development rights outside Greater China and the right to conduct clinical trials in the region. The announcement drove the share price up nearly 20% in after-hours trading. » Plus sur de.investing.com


  • Licensing deal with Amoytop sends Aligos Therapeutics stock higher

    Aligos Therapeutics granted an exclusive license for pevifoscorvir sodium to Xiamen Amoytop Biotech for Greater China and received a $25 million upfront payment. The deal includes up to $420 million in milestone payments and tiered royalties. Aligos retains rights for the U.S., Europe, South Korea, Japan and other markets, may run studies in Greater China, and Amoytop will fund the program there. The transaction is expected to extend Aligos’ cash runway into Q4 2026 and prompted a roughly 20% share price increase. » Plus sur de.investing.com

Données financières

Au dernier trimestre, Aligos Therapeutics Aktie a réalisé un chiffre d'affaires de 2,53 M € et un bénéfice net de -19,3 M €

(EUR) septembre 2026
YoY
Chiffre d'affaires 2,53 M 301,14 %
Bénéfice brut 2,53 M 301,14 %
Bénéfice net -19,3 M 28,19 %
EBITDA -19,01 M 27,52 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
8,09 M €
Nombre d'actions
6,25 M
Plus haut/bas sur 52 semaines
12,48 € - 1,11 €
Dividendes Non
Bêta
2,42
Ratio P/E
-0,22
Ratio PEG
0,00
Ratio P/B
1,31
Ratio P/S
0,26

Profil de l'entreprise

Nom
Aligos Therapeutics Aktie
PDG
Lawrence Blatt
Employés 82
🍪

Parqet  utilise des cookies. En savoir plus